J&J inks stem cell collaboration with Capricor – PharmaTimes
|
J&J inks stem cell collaboration with Capricor
PharmaTimes Under the terms of the agreement, J&J’s Janssen unit will help with the development of Capricor’s cell therapy programme for cardiovascular applications, including its lead product, CAP-1002. The latter is an allogeneic adult stem cell therapy derived … |
